International Journal of Endocrinology and Metabolism
Research Institute for Endocrine Sciences
Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Efficacy and Safety of Dapagliflozin in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fractions: A Systematic Review and Meta-Analysis
Journal of the Nepal Medical Association
April 2026
Duwadi B.
Open Access
SGLT2 Inhibitors and Long-Term Outcomes After AKI
Kidney International Reports
March 2026
Wannakittirat A.
Open Access
Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy
Acta Diabetologica
March 2026
Soyaltin U.
rs10010131A in WFS1 is Associated with Elevated Serum Urea in Type 2 Diabetes Patients Treated with SGLT2 Inhibitors
Therapeutics and Clinical Risk Management
2026
Naja K.
Open Access
SGLT2-inhibition and myocardial infarction size in patients with type 2 diabetes mellitus– Insights from an acute cardiovascular care center
BMC Cardiovascular Disorders
December 2025
Bojti I.
Open Access
ADD2Dia: Real-World Clinical Effectiveness of Adding a Sodium-Glucose Cotransporter 2 Inhibitor to Gliclazide-Based Therapy in Type 2 Diabetes
Advances in Therapy
December 2025
Moreira R.O.
Open Access
SGLT2 inhibitors reduce the risk of renal failure in CKD stage 5 patients with Type 2 DM
Scientific Reports
December 2025
Huang B.
Open Access
Ketone bodies in renal function and diabetic kidney disease
Journal of Nutritional Biochemistry
August 2025
Mechchate H.
Factors Associated with Response to SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Veterans with Type 2 Diabetes Mellitus †
Journal of Clinical Medicine
June 2025
Arora G.
Open Access
Fournier’s Gangrene in an HIV-Positive Patient Using a Sodium-Glucose Cotransporter-2 Inhibitor: A Case Report
Journal of Wound Management and Research
February 2025
Yoon W.
Open Access
Cardioprotective effectiveness of SGLT2 inhibitors in older diabetic women with early-stage breast cancer following anthracycline- and/or trastuzumab-based treatment
Therapeutic Advances in Medical Oncology
January-December 2025
Liu Y.S.
Open Access
Effect of SY009, a novel SGLT1 inhibitor, on the plasma metabolome and bile acids in patients with type 2 diabetes mellitus
Frontiers in Endocrinology
2025
Yang H.
Open Access
Recent updates and the state of the art of renal biochemistry
Renal Failure Insights from Nephrotic Syndrome to Systemic Renal Dynamics
1 January 2025
Ofori E.K.
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Biomedicines
September 2024
Caturano A.
Open Access
Effect of SGLT2 inhibitors on kidney function of type 2 diabetes patients during Ramadan: A systematic review
Qatar Medical Journal
2024
Waheed M.A.
Open Access
Antianginal effects of empagliflozin in patients with type 2 diabetes and refractory angina; a randomized, double-blind placebo-controlled trial (EMPT-ANGINA Trial)
Clinical Cardiology
January 2024
Mansouri M.H.
Open Access
Incident infection risks depending on oral antidiabetic exposure in insulin-treated type 2 diabetes patients
Scientific Reports
December 2023
Park S.
Open Access
Relationship between dapagliflozin and urinary albumin-to-creatinine ratio in patients with diabetes mellitus and cardiovascular disease: An observational study
Cardiology Plus
1 October 2023
Wu Z.
Open Access
SGLT2i and GLP-1 RA therapy in type 1 diabetes and reno-vascular outcomes: a real-world study
Diabetologia
October 2023
Anson M.
Open Access
How Low Can You Go? Safety and Efficacy of Sodium-Glucose Cotransporter Inhibitors in Decreased Renal Function
Journal of Pharmacy Practice
April 2023
Barvian C.K.
Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study
Journal of Clinical Endocrinology and Metabolism
1 April 2023
Edwards K.
Impact of sodium-glucose co-transporter 2 inhibitors on renal outcomes in patients of diabetes mellitus: A meta-analysis of landmark renal and cardiovascular outcome trials
Indian Journal of Pharmacology
March 2023
Bose D.
All Open Access, Green
Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: a structured qualitative assessment
Therapeutic Advances in Endocrinology and Metabolism
January-December 2023
Edwards K.
Open Access
Metabolic effects of sodium-glucose co-transporter 2 inhibitor
Clinical Endocrinology and Endocrine Surgery
26 December 2022
Kedyk A.V.
Open Access